Die Medizinische Universität Innsbruck wurde am 1. Jänner 2004 als eigenständige Universität gegründet und ging aus der bis dahin bestehenden Medizinischen Fakultät der Leopold-Franzens-Universität Innsbruck hervor. Ihr erster Rektor, also Gründungsrektor, war Hans Grunicke.

During the past decade, Medizinische Universität Innsbruck conducted 103 clinical trials. In the 10-year time frame, 103 clinical trials started and 35 clinical trials were completed, i.e. on average, 34% percent of trials that started reached the finish line to date. In the past 5 years, 54 clinical trials started and 25 clinical trials were completed. i.e. 46.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medizinische Universität Innsbruck" #1 sponsor was "Amgen" with 9 trials, followed by "Bayer" with 6 trials sponsored, "Celgene" with 6 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored and "Vertex Pharmaceuticals Incorporated" with 6 trials sponsored. Other sponsors include 97 different institutions and companies that sponsored additional 84 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medizinische Universität Innsbruck" #1 collaborator was "European Commission" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "ClinAssess GmbH" with 2 trials as a collaborator, "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator and "Hoffmann-La Roche" with 2 trials as a collaborator. Other collaborators include 59 different institutions and companies that were collaborators in the rest 67 trials.

According to Clinical.Site data, the most researched conditions in "Medizinische Universität Innsbruck" are "Cystic Fibrosis" (7 trials), "Ulcerative Colitis" (7 trials), "Cardiovascular Diseases" (4 trials), "Crohn's Disease" (4 trials) and "Acute Myeloid Leukemia" (3 trials). Many other conditions were trialed in "Medizinische Universität Innsbruck" in a lesser frequency.

Most popular intervention types in "Medizinische Universität Innsbruck" are "Drug" (98 trials), "Other" (26 trials), "Device" (15 trials), "Biological" (9 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "IVA" (5 trials), "Mirikizumab" (4 trials), "Dexamethasone" (3 trials) and "Standard of care" (3 trials). Other intervention names were less common.

The vast majority of trials in "Medizinische Universität Innsbruck" are 127 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Medizinische Universität Innsbruck". undefined are not yet recruiting, 33 are recruiting, 26 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 54 completed trials in Medizinische Universität Innsbruck, 1 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Medizinische Universität Innsbruck, 7 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 63 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 14 trials that are defined as “Not Applicable".

Medizinische Universität Innsbruck has several departments that took part in Clinical trials: "Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie" - 16 trials, "Medical University Innsbruck, Department of Neurology" - 15 trials, "Universitätsklinik für Innere Medizin" - 7 trials, "Medizinische Universität Innsbruck; Universitätsklinik für Innere Medizin I" - 2 trials